p.138 抽出テキスト

Lancet 2007; 369: 1090–1098. PMID: 17398308 1010. Domei T, Yokoi H, Kuramitsu S, et al. Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J 2012; 76: 423–429. PMID: 22156311 1011. Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165: 725–730. PMID: 15824290 1012. Ueki K, Sasako T, Okazaki Y, et al. J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5: 951–964. PMID: 29079252 1013. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–591. PMID: 18256393 1014. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589. PMID: 18784090 1015. Hong J, Zhang Y, Lai S, et al. SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013; 36: 1304–1311. PMID: 23230096 1016. Wanner C, Lachin JM, Inzucchi SE, et al. EMPA-REG OUTCOME Investigators. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation 2018; 137: 119–129. PMID: 28904068 1017. Wanner C, Inzucchi SE, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323–334. PMID: 27299675 1018. Fitchett D, Zinman B, Wanner C, et al. EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016; 37: 1526–1534. PMID: 26819227 1019. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117–2128. PMID: 26378978 1020. Kaku K, Lee J, Mattheus M, et al. EMPA-REG OUTCOME® Investigators. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®. Circ J 2017; 81: 227–234. PMID: 28025462 1021. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–1289. PMID: 16214598 1022. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180–1188. PMID: 17848652 1023. Nissen SE, Nicholls SJ, Wolski K, et al. PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561–1573. PMID: 18378631 1024. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311–322. PMID:27295427 1025. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834–1844. PMID: 27633186 1026. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247–2257. PMID: 26630143 1027. Holman RR, Bethel MA, Mentz RJ, et al. EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377: 1228–1239. PMID: 28910237 1028. Yokoyama H, Matsushima M, Kawai K, et al. Japan Diabetes Clinical Data Management Study Group. Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20). Diabet Med 2011; 28: 1221–1228. PMID: 21658121 1029. Sone H, Tanaka S, Tanaka S, et al. Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011; 96: 3448–3456. PMID: 21865372 1030. Saito I, Kokubo Y, Yamagishi K, et al. Diabetes and the risk of coronary heart disease in the general Japanese population: the Japan Public Health Center-based prospective (JPHC) study. Atherosclerosis 2011; 216: 187–191. PMID: 21300356 1031. Kadowaki S, Okamura T, Hozawa A, et al. NIPPON DATA Research Group. Relationship of elevated casual blood glucose level with coronary heart disease, cardiovascular disease and all-cause mortality in a representative sample of the Japanese population. NIPPON DATA80. Diabetologia 2008; 51: 575–582. PMID: 18197396 1032. Fujishima M, Kiyohara Y, Kato I, et al. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes 1996; 45 Suppl: S14–S16. PMID: 8674881 1033. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765–775. PMID: 17699010 1034. 日本糖尿病学会.糖尿病診療ガイドライン2016.南江堂 2016. 1035. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644–657. PMID: 28605608 1036. Mahaffey KW, Neal B, Perkovic V, et al. CANVAS Program Collaborative Group. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018; 137: 323–334. PMID: 29133604 1037. Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ 2016; 352: i1541. PMID: 27029385 1038. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA 2015; 314: 265–277. PMID: 26197187 1039. Levin D, Bell S, Sund R, et al. Scottish Diabetes Research Network Epidemiology Group, Diabetes and Cancer Research Consortium. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015; 58: 493–504. PMID: 25481707 1040. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486–494. PMID: 12876091 1041. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072–2077. PMID: 12086760 1042. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10–16. PMID: 14683737 1043. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327–1335. PMID:23992602 1044. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232–242. PMID: 26052984 1045. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317–1326. PMID: 23992601 1046. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013; 310: 1711–1720. PMID: 24150467 1047. Ahmed MB, Patel K, Fonarow GC, et al. Higher risk for incident heart failure and cardiovascular mortality among community-dwelling octogenarians without pneumococcal vaccination. ESC Heart Fail 2016; 3: 11–17. PMID: 27668089 1048. White HD, Chew DP. Acute myocardial infarction. Lancet 2008; 372: 570–584. PMID: 18707987 1049. Pedersen F, Butrymovich V, Kelbæk H, et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 2014; 64: 2101–2108. PMID: 25457398 1050. Piepoli MF, Corrà U, Dendale P, et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur J Prev Cardiol 2016; 23: 1994–2006. PMID: 27600690 1051. Goto Y. Current state of cardiac rehabilitation in Japan. Prog